A survey of Huntington's disease (HD) in Northern Ireland, with a population of 1-5 million, has shown a 1991 prevalence rate of 6-4/100 000. Virtually complete ascertainment was achieved, enabling prevalence rate estimates and age statistics to be calculated over the last 20 years. The prevalence rate is similar to the high prevalence rates of HD found in most European populations, suggesting the presence of either one extremely ancient or a number of separate mutational origins, resulting in a uniform European HD prevalence. The ages at diagnosis and duration of the disease are similar to previous studies, suggesting a consistent effect of the HD gene in all families. Estimates of heterozygote frequency (HF), direct and indirect mutation rate, fertility, and genetic fitness (W) were made. Reliable HF estimates gave values between 10 and 11 x 10-5. The direct and indirect mutation rates were 0-32 x 106 and 105 x 10-6 respectively. W was increased in the affected HD population but decreased in the at risk population. Fertility in HD is not reduced, but it appears that at risk patients have actively limited their family size. Factors responsible include, among others, the fear of developing HD and genetic counselling of families. This is the first published epidemiological survey to include ascertainment data in a population both before and after isolation of the HD gene, and with the diagnosis in virtually all patients confirmed by DNA mutation testing.
This study includes all familial cases and also cases with no definite or substantiated family history, all confirmed as HD on genetic testing. Inclusion of all possible cases is important to obtain a true reflection of the population epidemiology.
There have been few studies on Huntington's disease in Northern Ireland (NI). Stevenson' identified three families with HD referred from neurologists, and calculated a prevalence rate of 8 per million. Although the figure is a gross underestimate, it is similar to the historical estimate for south Wales. 6 In 1975, a further survey was initiated. This survey, which was over two years, used multiple sources of ascertainment. The findings were presented at a symposium on HD in London in 1976 (N C Nevin, unpublished data). There were 93 affected patients in a population of 1-536 million, giving a prevalence rate of 6-05 x 10-5. A review of the case records shows that some families did not have HD, and there was incomplete ascertainment. The survey was valuable in that it provided records on HD for the Department of Medical Genetics and alerted clinicians, including psychiatrists and neurologists, to the importance ofgenetic counselling for HD patients. The present survey was made easier, as these earlier records included full pedigrees and were an important source of ascertainment. No published prevalence rates for HD are available from the Republic of Ireland, except for County Donegal, with a prevalence of 1 6 per 100 000, low because of exceptional emigration and family size patterns.7 HD in Great Britain has been studied more than in any other part of the world. Prevalence rates are available for more than 15 Age (years) Figure 1 Risk of an unaffected subject at 50% prior risk for HD carrying the HD gene at a particular age. It is certain that new mutation patients do exist in the population. Goldberg et al47 have calculated a mutation rate of 3% from an analysis of DNA samples in an incomplete ascertainment of patients. Our own indirect mutation rate is 1-7% of the population. As new mutation cases often present with later onset and smaller repeat size, some cases may not yet have been ascertained. A new mutation rate of the order of 2 to 3% is realistic for HD. The likelihood of obtaining DNA from "normal" parents to confirm or exclude paternity and repeat sizes is small in such cases, and makes diagnostic confirmation difficult.
Of the studies that have calculated fertility and genetic fitness in Huntington's disease, a third show a decrease in fertility and fitness, a third show values close to normal levels, and a third show an increase.' The two main studies in the UK'839 both show an apparent increase in fertility and fitness. It would appear that within reliable studies, there is a static or slight but real increase in fertility and fitness. The reasons for this are unclear. In the Northern Ireland survey there is a significant increase in fertility and fitness when the affected cohort is compared to the at risk cohort. The difference is less marked when compared to the control population group. This reflects the heterozygote frequency figure which is lower than in most surveys. Most genetic diseases with an increased fitness imply selective biological advantage. It is unlikely that this is the case in HD, although an increase in HD owing to mutational bias has been suggested.48 An apparent lower incidence of cancers, even when corrected for age, has also been shown. 49 It is more likely that because the gene affects primarily the brain, the subject's ability to plan a family successfully is in some way inhibited. This is borne out by comparison of the female affected and at risk fertility figures which are much higher than average in the case ofaffected females and lower in at risk females compared to at risk males. It is possible that a small number of children of affected fathers may be lost to the study because of non-paternity, but 48% of the affected HD patients were male, and this is consistent with the relative lower male fertility rate. Other studies have shown varying results50 and no consistency has been found.
Earlier diagnosis and presymptomatic 
